– UK, London –  Spire Healthcare Group PLC (LON: SPI) today announced the appointment of Jenny Kay as an Independent Non-Executive Director with effect from 1 June 2019. Jenny has also been appointed a member of the Company’s Clinical Governance and Safety Committee.

Garry Watts, Spire’s Chairman, said: “We are delighted that Jenny has agreed to join Spire’s Board, she will bring considerable clinical experience, with a particular focus on nursing, from her years as a front line registered nurse and subsequently in senior management and board roles across the NHS. The appointment supports the Company’s commitment to quality in its hospitals and she will work closely with Dame Janet Husband in this area.”

About Jenny Kay

Jenny Kay is currently a non-executive director and senior independent director at East London NHS Foundation Trust, a large combined mental health and community organisation providing services across East London, Luton, and Bedfordshire. She was previously the Director of Nursing at Dartford and Gravesham NHS Trust in Kent amongst other quality improvements, she strengthened the role of the ward sister, resulting in improvements in patient experience, safety, and effectiveness on the wards. Jenny also worked at the Department of Health in the Chief Nursing Officer’s team, leading on Communications. Additionally, Jenny has experience as Director of Quality in a Clinical Commissioning Group.

Jenny’s clinical background is in children’s nursing – she was a ward sister at King’s College Hospital for many years, specialising in care for children with liver disease and children requiring intensive care. She trained at St Thomas’ and Guy’s Hospitals.

For more information: http://www.spirehealthcare.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.